Research programme: platinum-based anticancer therapeutics - CTI BioPharma

Drug Profile

Research programme: platinum-based anticancer therapeutics - CTI BioPharma

Alternative Names: BBR 3610; CT-3610; CT-47463; CT-47609; CT-47613

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Roche; University of Vermont
  • Developer CTI BioPharma
  • Class Platinum complexes
  • Mechanism of Action DNA cross linking agents; DNA synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Cancer

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Cancer in USA (IV)
  • 30 May 2014 Cell Therapeutics is now called CTI BioPharma
  • 02 Nov 2010 Cell Therapeutics receives grant from US Government Therapeutic Discovery Tax Credit program for Platinum-based anticancer therapies
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top